Objective To investigate the efficacy and safety of riboflavin sodium phosphate combined with interferon in the treatment of children with herpes isthmus.Methods 70 children with herpes isthmus treated at our hospital from February,2016 to February,2018 were randomly divided into a control group (n =35) and an observation group (n =35).The control group were treated with atomization inhalation of interferon,and the observation group with atomization inhalation of interferon and intravenous riboflavin sodium phosphate.After one week's continuous treatment,the efficacies of the two groups was evaluated and compared,and the improvement of symptoms and the incidence of adverse reactions were recorded and compared between the two groups.At the end of the treatment,the levels of serum inflammatory factors were compared between the two groups.Results The total effective rate of the observation group was 94.29％ (33/35),which was higher than that of the control group 77.14(27/35).The incidence of adverse reactions was lower in the observation group than in the control group [5.71％ (2/35) vs.22.86％ (8/35),P ＜ 0.05].The times for the disappearance of herpes ulcer and fever as well as hospital stay were (2.78±0.31) d,(1.39±0.34) d,and (5.41±0.74) d in the observation group,which were lower than those in the control group (all P ＜ 0.05).After the treatment,the levels of CRP,TNF-u,and IL-10 in the observation group was (4.51±0.79) ng/ml,(12.39±4.34) ng/L,and (23.12±6.11) ng/L,which were lower than those in the control group (all P ＜ 0.05).Conclusions Riboflavin sodium phosphate combined with interferon in the treatment of children with herpes isthmus is effective and safe and can relieve the children's inflammatory reaction and reduce adverse reactions.%目的 探讨核黄素磷酸钠与干扰素联合用于疱疹性咽峡炎的有效性与安全性.方法 选取本院2016年2月至2018年2月诊治的疱疹性咽峡炎患儿70例,根据随机数字表法将患儿分为对照组与观察组,各35例.对照组使用干扰素雾化吸入治疗,观察组使用干扰素雾化吸人联合核黄素磷酸钠静脉滴注治疗,连续用药1周后,评估并对比两组疗效,记录并比较两组各症状改善情况及不良反应发生率;分别于人院时、治疗结束时检测并比较两组血清炎症因子水平.结果 观察组治疗总有效率为94.29％(33/35),高于对照组的77.14％(27/35),差异有统计学意义(P＜0.05);治疗期间观察组不良反应发生率为5.71％(2/35),低于对照组的22.86％(8/35),差异有统计学意义(P＜0.05);观察组疱疹溃疡消退时间、退热时间、住院时间分别为(2.78±0.31)d、(1.39±0.34)d、(5.41 ±0.74)d,均短于对照组,差异均有统计学意义(均P＜ 0.05);治疗后,观察组CRP、TNF-α、IL-10水平分别为(4.51±0.79)ng/ml、(12.39±4.34) ng/L、(23.12±6.11) ng/L,均低于对照组,差异均有统计学意义(均P＜0.05).结论 核黄素磷酸钠与干扰素联合治疗小儿疱疹性咽峡炎疗效确切,患儿炎症反应明显减轻,不良反应减少,联合用药安全有效,应用价值高.
展开▼
